Clinical trial
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple…
NCT00049673 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00049673 |
|---|---|
| Title | Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma |
| Official title | A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | prednisone, thalidomide |
| Enrollment | 332 |
| Start date | Oct 15, 2002 |
| Primary completion | Oct 19, 2011 |
| Completion | Sep 19, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 13, 2023 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: